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Background
Cardioplexol® (Swiss Cardio Technologies) is a hyperka-
lemic, low-dose, single-shot cardioplegic solution which
offers immediate asystole of the heart, maintenance up
to 90 minutes and immediate reversal of asystole after
release of cross clamp. Intermittent crossclamping with
Lidoflazine is the current operative technique used in
our center. Main question was whether Cardioplexol is
an efficient, safe, easy-to-use and worthy alternative to
Lidoflazine in elective isolated CABG in low-risk
patients. Primary outcomes are heart enzymes (cTnI
and CK-MB) and secondary outcomes are operation
times, length of stay, major complications and in-hospi-
tal mortality.
Methods
From December 2011 to May 2013 40 patients, with
LVEF ≥50%, EuroSCORE II <3,5% and no severe sys-
temic disease, underwent elective CABG and were con-
secutively randomized to intermittent crossclamping
(ICC; n=20) or Cardioplexol (CPX; n=20). All were
operated on by the same surgeon.
Results
There was no significant difference in age (CPX 71.04
±8.54; ICC 67.25±9.90), EuroSCORE II (CPX 1.19±0.63;
ICC 1.11±0.46) or number of distal anastomoses (CPX
2.95±0.51; ICC 3.15±0.745). We found no significant dif-
ference for maximum cTnI (CPX 3.38±1.50; ICC 4.59
±4.23) or maximum CK-MB (CPX 23.99±13.95; ICC
25.50±20.10). ECC time (CPX 57.55±11.93; ICC 67.20
±21.78) and cross-clamp time (CPX 24.62±1.31; Lido
22.76±1.49) were not significantly different. Neither
length of hospital stay (CPX 9.10±2.32; ICC 8. 19±1,25)
nor postoperative complications (CPX 1.25±0.78; ICC
0.85±0.67) showed significant difference. There was no
in-hospital mortality.
Conclusion
In this elective CABG population with low risk, Cardio-
plexol offered good myocardial protection, with compar-
able primary and secondary outcomes. Further studies
are needed to expand its use.
Authors’ details
1University of Antwerp, Belgium. 2Department of Cardiac Surgery, Antwerp
University Hospital, Belgium.
Published: 11 September 2013
doi:10.1186/1749-8090-8-S1-P120
Cite this article as: Kairet et al.: Cardioplexol, a new cardioplegic
solution for elective CABG. Journal of Cardiothoracic Surgery 2013 8(Suppl
1):P120.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: koen.kairet@student.ua.ac.be
1University of Antwerp, Belgium
Full list of author information is available at the end of the article
Kairet et al. Journal of Cardiothoracic Surgery 2013, 8(Suppl 1):P120
http://www.cardiothoracicsurgery.org/content/8/S1/P120
© 2013 Kairet et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
